[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]

Lakartidningen. 2007;104(22):1684-8.
[Article in Swedish]
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Cohort Studies
  • Disability Evaluation
  • Disease Progression
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Peptides / therapeutic use*
  • Placebos
  • Prognosis
  • Registries
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Peptides
  • Placebos
  • Glatiramer Acetate
  • Interferon-beta